Pentoxifylline (PTX), a methylxanthine phosphodiesterase inhibitor, is primarily known for its use in treating microcirculatory disorders due to its hemorheological effects. PTX exhibits both anti-inflammatory and reno-protective effects via inhibiting important proinflammatory cytokines and interleukins including tumor necrosis factor- α (TNF-α), interferon-γ (IFN-γ) interleukin-1 (IL-1) and IL-6, and reducing oxidative stress. Progression of chronic kidney disease (CKD) is exacerbated by inflammation and oxidative stress, hence PTX can be potential candidate to help ameliorate proteinuria in CKD patients, thereby slowing CKD progression and further decline in kidney function. In addition, PTX has beneficial effects concerning anemia that is a common complication in CKD patients because of erythropoietin deficiency, abnormalities in iron homeostasis, and inflammation-induced erythropoiesis suppression. Erythropoiesis stimulating agents (ESAs) are considered the standard treatment of anemia in CKD patients, but ESAs often encounter resistance primarily mediated by persistent inflammation. Hence the anti-inflammatory effects of PTX can help improve the responsiveness to ESAs, thereby improving hemoglobin levels and reducing ESA dose requirements. Consequently, PTX can help prevent poor cardiovascular outcomes and reduced quality of life, specifically in patients with end stage renal disease (ESRD) on dialysis. The implications of these findings suggest that PTX could be a valuable addition to current treatment strategies, offering a comprehensive approach for management of CKD and its associated anemia. This review emphasizes the mechanisms underlying the reno-protective and anti-inflammatory properties of PTX and explores the therapeutic potential of PTX in clinical practice.